Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3551385rdf:typepubmed:Citationlld:pubmed
pubmed-article:3551385lifeskim:mentionsumls-concept:C0004611lld:lifeskim
pubmed-article:3551385lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:3551385lifeskim:mentionsumls-concept:C0085697lld:lifeskim
pubmed-article:3551385lifeskim:mentionsumls-concept:C0021149lld:lifeskim
pubmed-article:3551385pubmed:issue11lld:pubmed
pubmed-article:3551385pubmed:dateCreated1987-5-15lld:pubmed
pubmed-article:3551385pubmed:abstractTextOf 168 urine sediments, which were obtained from 55 patients with chronic pyelonephritis in the course of 3 years when a significant bacteriuria with E. coli was present, we demonstrated antibody-loaded bacteria in 81 cases (48.21%). In the active stage of the disease with 54.10% were found significantly more than in the inactive with 32.61%. In obstructive chronic pyelonephritis the positive rate was 54.79% in contrast to 43.16% in non-obstructive chronic pyelonephritis. While in the active stage of the obstructive chronic pyelonephritis with 57.41% more antibody-containing bacteria were excreted than with 47.31% in the inactive stage, the positive rate in the active stage of the non-obstructive chronic pyelonephritis was with 54.47% significantly increased in contrast to 22.22% in the inactive stage. 25.71% of the patients excreted only ACB+-, 34.29% only ACB(-)- and 40% ACB+- and ACB(-)-germs in the course of the disease. The ACB-positive quote was in rough forms with 62.50% statistically significantly increased in contrast to 45.54% in O-typable and 42.86% in non-O-typable strains. In the ACB+- group the immunofluorescence titres to the homologous strain and the C3-activator in the serum as well as the urine lysozyme were significantly higher than in the ACB(-)-group.lld:pubmed
pubmed-article:3551385pubmed:languagegerlld:pubmed
pubmed-article:3551385pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3551385pubmed:citationSubsetIMlld:pubmed
pubmed-article:3551385pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3551385pubmed:statusMEDLINElld:pubmed
pubmed-article:3551385pubmed:monthNovlld:pubmed
pubmed-article:3551385pubmed:issn0044-3611lld:pubmed
pubmed-article:3551385pubmed:authorpubmed-author:NimmichWWlld:pubmed
pubmed-article:3551385pubmed:authorpubmed-author:FalkenhagenUUlld:pubmed
pubmed-article:3551385pubmed:authorpubmed-author:HandschuckIIlld:pubmed
pubmed-article:3551385pubmed:authorpubmed-author:HackerKKlld:pubmed
pubmed-article:3551385pubmed:authorpubmed-author:RehbockAAlld:pubmed
pubmed-article:3551385pubmed:issnTypePrintlld:pubmed
pubmed-article:3551385pubmed:volume79lld:pubmed
pubmed-article:3551385pubmed:ownerNLMlld:pubmed
pubmed-article:3551385pubmed:authorsCompleteYlld:pubmed
pubmed-article:3551385pubmed:pagination609-18lld:pubmed
pubmed-article:3551385pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:3551385pubmed:meshHeadingpubmed-meshheading:3551385-...lld:pubmed
pubmed-article:3551385pubmed:meshHeadingpubmed-meshheading:3551385-...lld:pubmed
pubmed-article:3551385pubmed:meshHeadingpubmed-meshheading:3551385-...lld:pubmed
pubmed-article:3551385pubmed:meshHeadingpubmed-meshheading:3551385-...lld:pubmed
pubmed-article:3551385pubmed:meshHeadingpubmed-meshheading:3551385-...lld:pubmed
pubmed-article:3551385pubmed:meshHeadingpubmed-meshheading:3551385-...lld:pubmed
pubmed-article:3551385pubmed:meshHeadingpubmed-meshheading:3551385-...lld:pubmed
pubmed-article:3551385pubmed:meshHeadingpubmed-meshheading:3551385-...lld:pubmed
pubmed-article:3551385pubmed:meshHeadingpubmed-meshheading:3551385-...lld:pubmed
pubmed-article:3551385pubmed:meshHeadingpubmed-meshheading:3551385-...lld:pubmed
pubmed-article:3551385pubmed:year1986lld:pubmed
pubmed-article:3551385pubmed:articleTitle[Incidence of antibody-coated bacteria in patients with chronic pyelonephritis].lld:pubmed
pubmed-article:3551385pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3551385pubmed:publicationTypeEnglish Abstractlld:pubmed